Sign up for ICER's Weekly View Newsletter

 

Weekly View


August 14, 2026

From the desk of Priya Ranade

Good morning, everyone.

This week, ICER released a Draft Evidence Report assessing the comparative clinical effectiveness and value of two treatments for uncontrolled hypertension:

 

  • baxdrostat (Baxfendy™, AstraZeneca)


  • lorundrostat (Mineralys Therapeutics, Inc.)

 

This preliminary draft marks the midpoint of ICER’s eight-month process of assessing this treatment, and the findings within this document should not be interpreted as ICER’s final conclusions. ICER is accepting public comments on the Draft Report until September 9th.

Let's see what else happened this week...

 

ICER in the News

 

Analysis: How New Federal Policies and Lower List PricesAre Reducing 340B Savings

340B Report

340B Report investigated the impact of the Inflation Reduction Act and other federal policies on 340B savings. ICER’s President and CEO, Sarah K. Emond, MPP was interviewed for the piece:

 

“Multiple sources told 340B Report that the IRA’s Medicare Drug Price Negotiation Program has led some manufacturers to reduce list prices…Sarah Emond, president and CEO of the Institute for Clinical and Economic Review (ICER) a nonprofit healthcare economics research group that evaluates the cost-effectiveness of drugs and medical devices, said the policy does not mandate companies lower their WAC—it only sets a maximum price that Medicare is allowed to pay for the medicine. However, published MFPs give payers information for future negotiations on list prices, potentially making it more difficult for drugmakers to keep higher prices, Emond said.

 

Emond added that, theoretically, a drug company could reduce its WAC to lower the likelihood that its drug is selected for future IRA negotiations, since qualifying is based on gross spending.”

Informing the US Medicare Drug Price Negotiation for Trelegy Ellipta and Breo Ellipta: Evaluating the Impact of Real-World Evidence

Value in Health included an ICER research paper in the August Editor’s Choice collection. The paper highlights ICER’s clinical and cost-effectiveness assessment of Trelegy Ellipta and Breo Ellipta, two drugs that have been on the market since 2017 and 2013, to inform the Centers for Medicare and Medicaid Services drug price negotiation process.

 

ICER noted that observational evidence is more likely to be available after a drug’s launch and is often needed to examine outcomes, such as adherence and persistence, which randomized controlled trials are not designed to assess. ICER found that real-world evidence reported greater adherence and persistence for Trelegy Ellipta and Breo Ellipta compared with generic multiple-inhaler or multiple-daily-dosing products, resulting in differentiated value-based pricing.

 
Pharmaceutical News

MUST READS


More employers are dropping the largest PBMs

Axios

More corporations are cutting ties with the three biggest pharmacy benefit managers and striking deals with smaller rivals to help manage their drug costs, a new survey from the National Alliance of Healthcare Purchaser Coalitions found. The findings are the latest sign of a shift underway in employer-sponsored health care as companies grapple with soaring health costs and a threat of worker lawsuits tied to how well they manage plans.

Novel Drug Launches in Most-Favored-Nation Countries and Medicare Pricing Benchmarks

JAMA

Researchers from Yale and Peking University analyzed drug pricing in Medicare and in MFN countries. They found:

 

“In this analysis of single-source drugs and biologics likely eligible for GLOBE and GUARD models, approximately 60% had launched in more than 1 MFN country within 1 year after US launch, but only 40% in countries with combined adult populations comparable with Medicare, and only 1% in countries with comparable combined drug expenditures.

 

These findings suggest that, for newly approved novel therapeutics entering the GLOBE and GUARD models over time, pricing benchmarks may rely on a small number of countries with limited market size and may therefore be vulnerable to strategically delayed launches or price increases by manufacturers, an impact seemingly aligned with the current administration’s goals.”

Pfizer’s Xeljanz And Medicare: A Case Of Market Forces Overtaking Price Negotiation

Pink Sheet

Pfizer’s Xeljanz (tofacitinib) continues to undergo the Medicare price negotiation process even though its upcoming “maximum fair price” will never be implemented because the drug already faces generic competition.


The outcome raises questions about whether the government and company should spend the time, effort, and money negotiating lower prices in situations where market-based competition likely will produce the same result earlier.

National Priority Voucher Program Should Balance Speedy Reviews With Public Trust, Sponsors Say

Pink Sheet

Stakeholders want to ensure FDA review speed with the National Priority Voucher (NPV) program does not impact public trust in FDA decisions. And questions remain about whether the NPV program will be revamped or scraped.

Newsom promotes affordable insulin, but California’s generic label is off to a slow start

KFF Health News

Seven months after the launch of its own low-cost insulin brand, state health officials said California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each, significantly less than the $89 to $411 that the state says most popular brand names charge before any retail markups or consumer discounts.


While it represents a tiny amount of the state’s insulin pipeline, it marks the first time a state is competing against the three biggest insulin drugmakers — Eli Lilly, Sanofi, and Novo Nordisk — under its own prescription drug label. 

OTHER HEADLINES

 
 

Key Upcoming Dates

 
  • 9/16: Parkinson's Disease — Evidence Report
  • 10/1: Hypertension — Evidence Report
  • 10/15: Friedrich's Ataxia — Draft Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email